Biophage Pharma Retains Carpe DM for Investor Relations Services.MONTREAL -- Biophage Pharma Inc. (TSX-V: BUG), a biopharmaceutical company engaged in the development of new therapeutics and clinical diagnostics based on its leading expertise in immunology and phage therapy Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade only bacterial cells and, in the case of lytic , today announced that it has retained Carpe DM, Inc. to provide the Company with investor relations Investor relations The process by which the corporation communicates with its investors. services. In consideration of the services to be provided, the Company has agreed to pay a monthly retainer of $2,500 to Carpe DM, Inc.The initial term of the agreement is 6 months and may be extended. Carpe DM will also provide business development services. "We are very pleased to announce that Carpe DM will be working with us to expand our exposure to the US capital and pharmaceutical marketplaces. They have extensive experience and had great success working with small, technologically advanced companies," declared Dr. Rosemonde Mandeville, president and Chief Executive Officer of Biophage Pharma. "Following the recent announcement of a collaborative agreement with the Centre for Organic and Resource Enterprises (CORE) to seek new opportunities in the Australian, Pacific and European markets, Carpe DM will help accelerate the introduction of Biophage's nanosensors and technology platforms to the US market," added Dr. Mandeville. Carpe DM CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Stuart Fine said "Carpe DM is committed to deliver a clear, high-quality and relevant message to the stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. on Biophage behalf. Our goal is to help the Company assume a leadership position in the infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. field" About Carpe DM, Inc. Carpe DM Group located in Watchung, New Jersey Watchung is a Borough in Somerset County, New Jersey, United States. As of the United States 2000 Census, the borough population was 5,613. Watchung was incorporated as a borough by an Act of the New Jersey Legislature on March 23, 1926, from portions of North Plainfield , is a boutique provider of services that include Investor and Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most , Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. ,Business and Financial Consulting, Mergers and Acquisitions, Database Marketing, Strategic Alliances and Marketing Plans.Its diverse industry experience includes publishing, entertainment, Internet, pharmaceuticals, biotech, consumer products, software applications, computer hardware, medical devices, biometrics, law enforcement and investment/brokerage. Carpe DM does not have any interest, directly or indirectly, in the Company or in its securities, or any intent to acquire such interest, other than an ownership of 662,183 common shares and 231,755 warrants, representing 2.4% on a fully-diluted basis. The principal of Carpe DM is Mr. Stuart Fine. About Biophage Pharma Inc. Biophage Pharma Inc. is a Canadian biopharmaceutical company developing new therapeutic and diagnostic products using phage-based technology. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 16 people, including a team of 13 researchers. Through an active research and development program, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new therapeutics collaboration agreements, Biophage is building a portfolio of promising new therapeutics (www.biophage.com). Biophage Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BUG) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion